Michael S. Cookson, MD, MMHC

Michael S. Cookson, MD, MMHC

University of Oklahoma College of Medicine

Oklahoma City, Oklahoma

Michael S. Cookson, MD, MMHC, is Professor and Chairman of the Department of Urology and holds the Donald D. Albers Endowed Chair in Urology at the University of Oklahoma Health Sciences Center in Oklahoma City. He has authored some 240 peer-reviewed journal publications as well as more than 30 chapters of various textbooks, and he is nationally recognized for his outstanding contributions to urologic oncology. Dr. Cookson completed his Urology Residency at the University of Texas, San Antonio, and completed his Urologic Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in New York. From 1998 to 2013, he served as the Vice Chairman of Urologic Surgery and Director of the Urologic Oncology Fellowship Program at Vanderbilt University. Dr. Cookson has devoted much of his academic career to the management of patients with urologic cancers, with a strong emphasis on clinical guidelines, education, and evidenced-based medicine. He was a member of the AUA/ABU Examination Committee for 10 years, serving as Oncology Consultant and Pathology Editor. He also serves on the ABU Oral Examination Committee. He is a Co-Founder of the Oncology Knowledge Assessment Test (OKAT), an SUO-mandated examination. He also served as Chair for the OKAT for 5 years. In 2011, he received the President’s Distinguished Service Award from the SUO for educational contributions. He received the 2018 AUA Presidential Citation for Outstanding Service for his role in the development of the OKAT and as Chair of the Castration-Resistant Prostate Cancer Guidelines Committee at the AUA 2018 Annual Meeting. Dr. Cookson has previously served as a member of the AUA Guidelines on Localized Prostate Cancer Committee. Dr. Cookson is currently serving out the 2019-2020 term as the SUO President.

Disclosures:

Talks by Michael S. Cookson, MD, MMHC

Integrating the AUA Guidelines into Your Practice

Integrating the AUA Guidelines into Your Practice

Posted by | Apr 2018

Michael S. Cookson, MD, MMHC, describes how urologists can use American Urological Association (AUA) guidelines to better manage metastatic castration resistant prostate cancer (mCRPC) patients. He stresses the importance of urologists serving as the primary caregiver, the multidisciplinary care model, and organized sequencing of treatments and therapeutics.

Read More
Enhanced Techniques of Non-Muscle Invasive Bladder Cancer Detection

Enhanced Techniques of Non-Muscle Invasive Bladder Cancer Detection

Posted by | Feb 2018

Michael S. Cookson, MD, describes the components of a quality transurethral resection of bladder tumor (TURBT), enhanced detection technologies such as blue light cystoscopy and narrow band imaging (NBI), and the induction of these new technologies into the American Urological Association (AUA) and Society of Urologic Oncology (SUO) bladder cancer guidelines and common practice.

Read More
BCG Failure: BCG Maintenance Should be Less Intense

BCG Failure: BCG Maintenance Should be Less Intense

Posted by | Jan 2018

Dr. Erik P. Castle, MD, explains the Southwest Oncology Group’s (SWOG’s) protocol for administering maintenance doses of bacillus Calmette-Guerin (BCG) to non-muscle invasive bladder cancer patients. He argues that carrying out the full SWOG course makes a positive impact on patients’ recurrence free survival rates, identifying the ideal disease types and patients to receive the full course.

Read More

Join the GRU Community

- Why Join? -